Standout Papers

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL 2006 2026 2012 2019 946
  1. Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL (2006)
    Hagop M. Kantarjian, Francis J. Giles et al. New England Journal of Medicine

Immediate Impact

1 by Nobel laureates 22 from Science/Nature 79 standout
Sub-graph 1 of 19

Citing Papers

Management of ALL in adults: 2024 ELN recommendations from a European expert panel
2024 Standout
Response and Resistance to BCR-ABL1-Targeted Therapies
2020 Standout
54 intermediate papers

Works of Lydia Wunderle being referenced

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
2007
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
2006 Standout
and 3 more

Author Peers

Author Last Decade Papers Cites
Lydia Wunderle 1187 721 456 530 17 1.4k
Clarisse Lobo 1264 1092 141 639 23 1.5k
P. Rae 958 663 166 468 8 1.4k
Deborah Thomas 968 439 736 371 19 1.3k
Phuong Dang 1362 1119 133 632 30 1.6k
Kerry Taylor 1542 1124 150 706 28 2.0k
Guillermo Garcia‐Manero 1301 819 269 270 34 1.7k
Chao Zhu 1788 1496 271 1009 48 2.2k
Albert Hoenekopp 1574 1309 189 836 21 1.8k
Ron Paquette 1716 1133 293 614 23 2.2k
Kasia Kozlowski 697 657 132 301 16 1.2k

All Works

Loading papers...

Rankless by CCL
2026